Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry.

J Am Acad Dermatol · 2022 · PMC8443529 · PMID 34537252

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendP = .07so close (0.05 < p ≤ 0.1)

Patients on biologic therapy reported dyspnea less frequently (biologic 1/25, 4.0%; nonbiologic 23/110, 20.9%, P = .04) but showed a trend toward increased HS flares (biologic 12/25, 48.0%; nonbiologic 32/110, 29.4%, P = .07) and longer time to COVID-19 resolution (biologic: median (interquartile range) 21 (14-31) days; nonbiologic: 14 (9-25) days, P = .07).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.